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Abstract
Metformin is the most widely used hypoglycemic agent. 
Besides its conventional indications, increasing evidence 
demonstrate a potential efficacy of this biguanide as an 
anticancer drug. Possible mechanisms of actions seem to 
be independent from its hypoglycemic effect and seem 
to involve the interference with key pathways in cellular 
proliferation and glycolysis. To date, many clinical trials 
implying the use of metformin in cancer treatment are 
on-going. The increasing use of 18F-2-fluoro-2-deoxy-
d-glucose positron emission tomography (FDG-PET) in 
cancer evaluation raises a number of questions about the 
possible interference of the biguanide on FDG distribution. 
In particular, the interferences exerted by metformin 
on AMP-activated protein kinase pathway (the cellular 
energy sensor), on insulin levels and on Hexokinase could 
potentially have repercussion on glucose handling and 
thus on FDG distribution. A better comprehension of the 
impact of metformin on FDG uptake is needed in order 
to optimize the use of PET in this setting. This evaluation 
would be useful to ameliorate scans interpretation in 
diabetic patients under chronic metformin treatment 
and to critically interpret images in the context of clinical 
trials. Furthermore, collecting prospective data in this 
setting would help to verify whether FDG-PET could be a 
valid tool to appreciate the anticancer effect of this new 
therapeutic approach.
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Core tip: Given the recent increasing number of clinical 
trials involving the use of metformin as anticancer 
agent and with the widespread use of 18F-2-fluoro-2-
deoxy-d-glucose positron emission tomography (FDG-
PET), this editorial deals with a critical evaluation of 
the main variables regulating FDG uptake that could be 
potentially influenced by the biguanide. This analysis 
could optimize not only the interpretation of PET images 
in diabetic patients but could also help to verify whether 
FDG-PET could be a valid tool to appreciate anticancer 
potential of this new therapeutic approach thus opening 
a new window on clinical trials.
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INTRODUCTION
Due to its safety, tolerability, and a very low incidence 
of lactic acidosis[1], metformin is the most widely 
prescribed oral hypoglycemic agent and exerts this 
effect by reducing hepatic glucose production and by 
increasing insulin sensitivity as well as glucose use 
by peripheral tissues[2,3]. Besides diabetes and other 
established indications for metformin[4,5], increasing 
evidence demonstrate a possible efficacy of this agent 
as an anticancer drug[6].
METFORMIN AND CANCER 
The hypothesized beneficial actions of metformin 
against cancer involve different and not yet fully clarified 
mechanisms. A key role is believed to be mediated 
by AMP-activated protein kinase (AMPK), a major 
player in the regulation of metabolism and growth, for 
both normal and cancer cells[7]. The activation of this 
molecule results from a decrease in mitochondrial ATP 
production due to the direct inhibition of metformin 
on respiratory complex Ⅰ[8] and consequently of the 
mammalian target of rapamycin. This effect induces 
cell cycle arrest and inhibits protein synthesis in cancer 
cells. However, more recent data have suggested that 
metformin can also regulate cancer cell biology in an 
AMPK-independent manner through the inhibition of the 
unfolded protein response with a consequent apoptosis, 
preventing angiogenesis and exerting toxicity on cancer 
stem cells[9].
Several recent epidemiological, animal, and cellular 
studies support these findings and a recent meta-
analysis has highlighted a correlation between decreased 
incidence of cancer and treatment with metformin in 
type Ⅱ diabetes patients[10-12].
Taken together these findings have encouraged 
more than 100 clinical trials on the effect of this drug 
in cancer patients, including prevention, adjuvant 
treatment and palliative treatment (cfr. on the NIH 
ClinicalTrials.gov web site[13]).
METFORMIN AND FDG-PET 
IMAGING: TECHNICAL AND CLINICAL 
IMPLICATIONS
The increasing widespread use of 18F-2-fluoro-2-
deoxy-d-glucose positron emission tomography (FDG-
PET) for the imaging of neoplastic disease[14] raises a 
number of questions about the possible technical and 
clinical implication of metformin on this technique.
In particular, can metformin interfere with FDG 
distribution in the whole body or in cancer tissue? 
And, if so, how should we interpret FDG PET scans 
in diabetic patients under chronic treatment with the 
biguanide? Finally, can this tracer be used to test 
and assess the antineoplastic effect of metformin on 
cancer? 
In clinical practice, the use of FDG-PET to non-
invasively diagnose, monitor, and evaluate treatment 
response of cancers is well established from many 
years[15]. This concept was extended from the observation 
by Di Chiro et al[16] who firstly demonstrated that 
FDG was more avidly accumulated in human brain 
tumors than in surrounding brain as well as in tumor 
recurrence. 
The evaluation of gastro-intestinal tract is a well-
known pitfall in FDG-PET imaging interpretation. 
Actually, metformin leads to intense, diffusely increased 
intestinal FDG in the colon, and to a lesser extent in 
the small bowel[17]. This effect can limit the diagnostic 
capabilities of FDG-PET/CT scanning and may mask 
gastrointestinal malignancies potentially resulting in 
incorrect cancer staging, inability to detect second 
primary cancers and inability to assess response to 
therapy[18,19]. To solve this problem, some authors 
proposed drug discontinuation before imaging with 
different schemes[20,21], in order to improve image 
analysis. However, to date there is no agreement 
about which is the best approach and feasibility and 
washout duration still have to be verified in the clinical 
setting. 
Our group[22] has tried to elucidate the determinants 
of high intestinal 18F-FDG radioactivity content in a mouse 
model, treated with long- or short-term metformin 
administration. We showed that this phenomenon, 
appearing after a relatively long period of treatment 
and persisting soon after drug washout, was related 
to biguanide-induced modifications in the gut cell 
phenotype and was characterized by an ATP-depletion 
with the consequent increased phosphorylated-AMPK 
levels and reduced TXNIP gene expression. 
With these premises, it is evident that the consequences 
of metformin treatment on FDG-PET scans are difficult 
to predict. On one side, as a drug with anti-proliferative 
activity metformin should decrease FDG uptake; on the 
other side, by activating AMPK in tumors, it would be 
expected to increase their glucose metabolism.
A further factor that has to be taken into account 
when we use FDG in cancer evaluation during metformin 
treatment is insulin asset[23]. As mentioned before, 
some recent experimental models have reported that 
one of the possible mechanism by which metformin 
could exert an antineoplastic activity, is its capability 
to lower both glucose and insulin levels in type II 
diabetes patients[24,25]. In order to examine this aspect, 
Mashhedi et al[26] studied FDG distribution in an 
example of insulin-responsive tumor. In a murine colon 
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cancer model, they found that metformin exposure 
did not affect insulin levels nor tumor FDG uptake in 
normo-insulinemic mice while decreased insulin levels 
and FDG uptake in hyper-insulinemic mice suggesting 
that, at least in this model, in neoplastic tissue the 
effect of this compound on insulin levels was more 
important than any AMPK activation.
This observation would imply carefulness in the 
evaluation of clinical trials using metformin in cancer 
treatment because its effect could be limited to hyper-
insulinemic subjects with insulin sensitive neoplasms. 
As a consequence, it has also important implications 
on for the interpretation of FDG-PET images and 
on for understanding influences of exerted by host 
metabolism and metformin on tumor behavior.
Another important role of metformin that could 
be involved in antineoplastic activity and thus can 
interfere with FDG uptake, is its capability to directly 
and selectively inhibit the enzymatic function of 
hexokinase (HK) Ⅰ and Ⅱ as demonstrated by Marini 
et al[27]. This work extended previous evidence about 
metformin in vitro effect in different cancer models 
such as CALU-1 cells as a model of non-small cell 
lung cancer[28] and in MDA-MB231 as a model of triple 
negative breast cancer. In all these cells metformin 
determined a dose- and time-dependent reduction in 
FDG uptake, in agreement with the expected effect of 
the biguanide on AMPK phosphorylation. Interestingly, 
this molecular mechanisms rely on the dislocation 
of HK from outer mitochondrial membrane with a 
consequent loss of enzymatic functional properties.
By interfering with HK activity, a rate limiting step 
of glucose consumption, metformin could influence 
FDG uptake. In fact, even if unquestionable evidence 
attesting that it is the exact surrogate and has the 
same metabolic fate of glucose is still lacking, we 
know that this tracer enters within the cell through 
the same facilitative transporters of glucose, is 
then phosphorylated by HK to FDG6P and remains 
trapped within cytosol, preventing all further glycolytic 
reactions. 
Obviously, all these findings cannot be easily 
transferred in clinical practice due to the high doses 
needed to induce this response (750 mg/kg per 
day) in mice. However, they rise up some interesting 
reflections. Metformin could influence some important 
determinants of FDG uptake in the different tissue: 
by lowering serum glucose and insulin levels it could 
modify tracer availability in the blood, reducing the 
usual competition between glucose and FDG for 
GLUT-1 receptor and other glucose transport proteins. 
This could lead to an increase in tracer availability 
for lesion uptake making the simple measurement of 
lesion tracer uptake (the so called SUV) a suboptimal 
index of lesion metabolism.
Even more complex is to establish whether FDG-
PET could represent a correct technique in for the 
assessment of the potential antineoplastic effect of 
metformin in the clinical setting.
In this line, it is of primary importance to understand 
how metformin could modulate PET signal in order 
to correctly verify whether this technique is useful to 
asses any therapeutic response.
This task is particularly relevant when metformin 
is used as adjuvant with other conventional therapy 
such as chemotherapeutic agents able to alter FDG 
distribution per se.
In apparent disagreement with other evidence[27], 
Habibollahi et al[29] showed that, in two colon cancer 
models, metformin increased 18F-FDG uptake soon 
after initiation of treatment. However, as the cells 
die from the effects of the biguanide and other 
chemotherapies, 18F-FDG uptake should eventually 
decrease. But this possible biphasic response on 
18F-FDG PET scans could confound the evaluation 
of therapeutic efficacy leading to an incorrect 
classification of patients as non-responders on the 
basis of an earlier scan.
To date, present available clinical trial results on 
the use of metformin as anticancer agent involve 
intermediate or surrogate outcome measurements, 
such as changes in cellular proliferation or hormone 
levels, rather than direct measures of clinical benefit and 
thus do not allow definitive conclusions. Furthermore, 
with respect to the colon, available data deal with the 
effects of metformin, at least in non-diabetic subjects, 
on normal epithelial cells rather than cancer cells 
and thus hypotheses concerning the use of this drug 
for prevention rather than for treatment are more 
feasible[30].
FUTURE DIRECTIONS
Prospective trials in diabetic patients submitted to 
routine FDG-PET scans are mandatory to verify if 
FDG-PET can be used as an early marker of response 
or if metformin interference with FDG distribution is 
significant enough to prevent its use in this setting 
and, in this case, if the use of proliferation markers 
would be preferable as appropriate choice to image the 
response of tumors.
To this purpose, a possible approach could be 
the use of compartmental analysis of tracer through 
dynamic PET acquisition in order to measure cancer 
glucose consumption in absolute terms (micromole/
min/g) and to obtain information about the possible 
relationship with lesion progression and therapeutic 
response.
CONCLUSION
FDG PET is useful to evaluate cancer metabolism 
in response to the different interventions. In order 
to establish if this technique could be a valid tool to 
appreciate anticancer potential of new therapeutic 
approach such as metformin, a better comprehension 
of all the variables that could interfere with FDG uptake 
is needed and further studies in this field are required.
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